With predators knocking, Shire needs to go on the hunt, analysts say

Save

They say the best defense is a good offense, and that just may be the case for Shire. Amid pharma's ongoing deal frenzy, the Dublin-based company–a prime target in light of its tax-friendly Irish locale–will need to make its own buys if it doesn't want to get swept up, analysts say.